BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042-1047. [PMID: 21674732 DOI: 10.1002/ibd.21800] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lee YJ, Kim SE, Park YE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID]. Korean J Gastroenterol 2021;78:117-28. [PMID: 34446634 DOI: 10.4166/kjg.2021.110] [Reference Citation Analysis]
3 Gresham LM, Marzario B, Dutz J, Kirchhof MG. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. J Am Acad Dermatol 2021;84:1652-66. [PMID: 33482251 DOI: 10.1016/j.jaad.2021.01.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
4 Zacharopoulou E, Orfanoudaki E, Tzouvala M, Tribonias G, Kokkotis G, Kitsou V, Almpani F, Christidou A, Viazis N, Mantzaris GJ, Tsafaridou M, Karmiris K, Theodoropoulou A, Papathanasiou E, Zampeli E, Michopoulos S, Tigkas S, Michalopoulos G, Laoudi E, Karatzas P, Mylonas I, Kyriakos N, Liatsos C, Kafetzi T, Theocharis G, Taka S, Panagiotopoulou K, Koutroubakis IE, Bamias G. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflamm Bowel Dis 2022:izac068. [PMID: 35394529 DOI: 10.1093/ibd/izac068] [Reference Citation Analysis]
5 Caldera F, Saha S, Ley D, Hayney MS. Vaccination of patients with inflammatory bowel disease. J Am Pharm Assoc (2003) 2016;56:591-3. [PMID: 27594110 DOI: 10.1016/j.japh.2016.07.005] [Reference Citation Analysis]
6 Yalchin M, Baker AM, Graham TA, Hart A. Predicting Colorectal Cancer Occurrence in IBD. Cancers (Basel) 2021;13:2908. [PMID: 34200768 DOI: 10.3390/cancers13122908] [Reference Citation Analysis]
7 Lee CK. [Ideal vaccination strategy in inflammatory bowel disease]. Korean J Gastroenterol 2015;65:159-64. [PMID: 25797379 DOI: 10.4166/kjg.2015.65.3.159] [Reference Citation Analysis]
8 Chen RE, Gorman MJ, Zhu DY, Carreño JM, Yuan D, VanBlargan LA, Burdess S, Lauffenburger DA, Kim W, Turner JS, Droit L, Handley SA, Chahin S, Deepak P, O'Halloran JA, Paley MA, Presti RM, Wu GF, Krammer F, Alter G, Ellebedy AH, Kim AHJ, Diamond MS. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors. Med (N Y) 2021;2:1327-1341.e4. [PMID: 34812429 DOI: 10.1016/j.medj.2021.11.004] [Reference Citation Analysis]
9 Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J, Segal JP, Sebastian S, Selinger CP, Parkes M, Smith PJ, Dhar A, Subramanian S, Arasaradnam R, Lamb CA, Ahmad T, Lees CW, Dobson L, Wakeman R, Iqbal TH, Arnott I, Powell N; Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol 2021;6:218-24. [PMID: 33508241 DOI: 10.1016/S2468-1253(21)00024-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 25.0] [Reference Citation Analysis]
10 Dezfoli S, Horton HA, Thepyasuwan N, Berel D, Targan SR, Vasiliauskas EA, Dubinsky M, Shih DQ, Kaur M, McGovern DP, Ippoliti A, Feldman EJ, Melmed GY. Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1754-1760. [PMID: 25985242 DOI: 10.1097/mib.0000000000000448] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
11 Toritani K, Kimura H, Kunisaki R, Watanabe J, Kunisaki C, Ishibe A, Chiba S, Inayama Y, Endo I. Uselessness of Serum p53 Antibody for Detecting Colitis-associated Cancer in the Era of Immunosuppressive Therapy. In Vivo 2020;34:723-8. [PMID: 32111776 DOI: 10.21873/invivo.11830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y). 2014;10:355-363. [PMID: 25013388 DOI: 10.1111/j.1440-1746.1995.tb01108.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Wellens J, Colombel JF, Satsangi JJ, Wong SY. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges. J Crohns Colitis 2021;15:1376-86. [PMID: 33721882 DOI: 10.1093/ecco-jcc/jjab046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mason A, Anver H, Lwin M, Holroyd C, Faust SN, Edwards CJ. Lupus, vaccinations and COVID-19: What we know now. Lupus 2021;:9612033211024355. [PMID: 34134555 DOI: 10.1177/09612033211024355] [Reference Citation Analysis]
15 Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2022:gutjnl-2021-326784. [PMID: 35477864 DOI: 10.1136/gutjnl-2021-326784] [Reference Citation Analysis]
16 Hisamatsu T. Management of inflammatory bowel disease during the COVID-19 pandemic. Immunol Med 2021;:1-8. [PMID: 34530694 DOI: 10.1080/25785826.2021.1978205] [Reference Citation Analysis]
17 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Caldera F, Ley D, Hayney MS, Farraye FA. Optimizing Immunization Strategies in Patients with IBD.Inflamm Bowel Dis. 2021;27:123-133. [PMID: 32232388 DOI: 10.1093/ibd/izaa055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Nguyen HT, Minar P, Jackson K, Fulkerson PC. Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease. World J Gastroenterol 2017; 23(42): 7644-7652 [PMID: 29204064 DOI: 10.3748/wjg.v23.i42.7644] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
20 Zeng H, Wang S, Chen L, Shen Z. Biologics for Psoriasis During the COVID-19 Pandemic. Front Med (Lausanne) 2021;8:759568. [PMID: 34938746 DOI: 10.3389/fmed.2021.759568] [Reference Citation Analysis]
21 Wieringa JW, van der Woude CJ. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2020;44-45:101665. [PMID: 32359679 DOI: 10.1016/j.bpg.2019.101665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Hertzell KB, Pauksens K, Rombo L, Knight A, Vene S, Askling HH. Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine 2016;34:650-5. [DOI: 10.1016/j.vaccine.2015.12.029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
23 Aikawa NE, França IL, Ribeiro AC, Sallum AM, Bonfa E, Silva CA. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine 2015;33:604-9. [PMID: 25554240 DOI: 10.1016/j.vaccine.2014.12.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
24 Kantsø B, Halkjær SI, Thomsen OØ, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved H, Ingels H, Petersen AM. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease. Vaccine 2015;33:5464-9. [DOI: 10.1016/j.vaccine.2015.08.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
25 Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis 2017;11:263-73. [PMID: 27797918 DOI: 10.1093/ecco-jcc/jjw188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
26 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
28 Cao Y, Zhao D, Xu AT, Shen J, Ran ZH. Effects of immunosuppressants on immune response to vaccine in inflammatory bowel disease. Chin Med J (Engl) 2015;128:835-8. [PMID: 25758282 DOI: 10.4103/0366-6999.152683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
29 Stobaugh DJ, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol. 2013;6:43-49. [PMID: 23818801 DOI: 10.2147/ceg.s42514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
30 Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van Geel N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies? Drugs R D 2021;21:341-50. [PMID: 34106430 DOI: 10.1007/s40268-021-00349-0] [Reference Citation Analysis]
31 Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00267-X. [PMID: 34116972 DOI: 10.1016/j.dld.2021.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 2021;84:1254-68. [PMID: 33422626 DOI: 10.1016/j.jaad.2020.12.058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
33 Müller KE, Dohos D, Sipos Z, Kiss S, Dembrovszky F, Kovács N, Solymár M, Erőss B, Hegyi P, Sarlós P. Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.02.027] [Reference Citation Analysis]
34 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 563] [Article Influence: 170.5] [Reference Citation Analysis]
35 Askling HH, Rombo L, van Vollenhoven R, Hallén I, Thörner Å, Nordin M, Herzog C, Kantele A. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis 2014;12:134-42. [PMID: 24529746 DOI: 10.1016/j.tmaid.2014.01.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 6.9] [Reference Citation Analysis]
36 Long MD, Gulati A, Wohl D, Herfarth H. Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease: A Practical Case-based Approach. Inflamm Bowel Dis 2015;21:1993-2003. [PMID: 25966839 DOI: 10.1097/MIB.0000000000000395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
37 Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, Kitchen M, Köller M, Kollaritsch H, Kundi M, Lassmann H, Mutz I, Pickl WF, Riedl E, Sibilia M, Thalhammer F, Tucek B, Zenz W, Zwiauer K. [Guidelines for vaccination of immunocompromised individuals]. Wien Klin Wochenschr 2016;128 Suppl 4:337-76. [PMID: 27457874 DOI: 10.1007/s00508-016-1033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
38 Banaszkiewicz A, Gawronska A, Klincewicz B, Kofla-Dłubacz A, Grzybowska-Chlebowczyk U, Toporowska-Kowalska E, Malecka I, Stryczynska-Kazubska J, Feleszko W, Lazowska-Przeorek I, Karolewska-Bochenek K, Walkowiak J, Slusarczyk J, Radzikowski A, Demkow U, Albrecht P. Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study. Inflamm Bowel Dis 2017;23:847-52. [PMID: 28394806 DOI: 10.1097/MIB.0000000000001076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. Gastroenterology 2021;161:681-700. [PMID: 34334167 DOI: 10.1053/j.gastro.2021.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist C, Posfay-barbe KM; the Swiss Inflammatory Bowel Disease Cohort Study Group. High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. Am J Gastroenterol 2019;114:1130-41. [DOI: 10.14309/ajg.0000000000000289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
41 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication). Intest Res 2018;16:178-93. [PMID: 29743831 DOI: 10.5217/ir.2018.16.2.178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
42 Magro F, Abreu C. Immunisations in Crohn's disease: Who? Why? What? When? Best Practice & Research Clinical Gastroenterology 2014;28:485-96. [DOI: 10.1016/j.bpg.2014.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
43 Choi AJ, Atteberry P, Lukin DJ. Vaccination in the Elderly and IBD. Curr Treat Options Gastroenterol 2019;17:492-505. [PMID: 31686385 DOI: 10.1007/s11938-019-00257-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112:241-258. [PMID: 28071656 DOI: 10.1038/ajg.2016.537] [Cited by in Crossref: 218] [Cited by in F6Publishing: 176] [Article Influence: 43.6] [Reference Citation Analysis]
45 Murthy SK, Kuenzig ME, Windsor JW, Ghia JE, Griffiths AM, Panaccione R, Seow CH, Benchimol EI, Bernstein CN, Bitton A, Huang JG, Jones JL, Lee K, Kaplan GG, Mukhtar MS, Tandon P, Targownik LE, Gibson DL. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. J Can Assoc Gastroenterol 2021;4:S54-60. [PMID: 34755040 DOI: 10.1093/jcag/gwab033] [Reference Citation Analysis]
46 Gregory MH, Ciorba MA, Wiitala WL, Stidham RW, Higgins P, Morley SC, Hou JK, Feagins LA, Govani SM, Cohen-Mekelburg SA, Waljee AK. The Association of Medications and Vaccination with Risk of Pneumonia in Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:919-25. [PMID: 31504531 DOI: 10.1093/ibd/izz189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
47 Lester R, Lu Y, Tung J. Survey of Immunization Practices in Patients With Inflammatory Bowel Disease Among Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr 2015;61:47-51. [PMID: 25611033 DOI: 10.1097/MPG.0000000000000730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Wine-lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. Journal of the American Academy of Dermatology 2013;69:1003-13. [DOI: 10.1016/j.jaad.2013.06.046] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
49 Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response. Dig Dis Sci 2016;61:1622-7. [DOI: 10.1007/s10620-015-3992-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
50 Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79-99. [PMID: 23569399 DOI: 10.2147/dhps.s28801] [Cited by in Crossref: 124] [Cited by in F6Publishing: 69] [Article Influence: 13.8] [Reference Citation Analysis]
51 Alexander JL, Selinger CP, Powell N; British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group. Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol 2021;6:987-8. [PMID: 34653395 DOI: 10.1016/S2468-1253(21)00374-5] [Reference Citation Analysis]
52 Desalermos A, Pimienta M, Kalligeros M, Shehadeh F, Diamantopoulos L, Karamanolis G, Caldera F, Farraye FA. Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021:izab266. [PMID: 34849941 DOI: 10.1093/ibd/izab266] [Reference Citation Analysis]
53 Shehab M, Abu-Farha M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Alphonse Thanaraj T, Channanath A, Ali H, Abubaker J, Almulla F. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. J Clin Med 2021;10:5362. [PMID: 34830644 DOI: 10.3390/jcm10225362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease: Biologics therapy in East Asia. Journal of Gastroenterology and Hepatology 2017;32:769-77. [DOI: 10.1111/jgh.13612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
55 Mishra RPN, Yadav RSP, Jones C, Nocadello S, Minasov G, Shuvalova LA, Anderson WF, Goel A. Structural and immunological characterization of E. coli derived recombinant CRM197 protein used as carrier in conjugate vaccines. Biosci Rep 2018;38:BSR20180238. [PMID: 29875175 DOI: 10.1042/BSR20180238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Ufer M, Shakeri-Nejad K, Gardin A, Su Z, Paule I, Marbury TC, Legangneux E. Impact of siponimod on vaccination response in a randomized, placebo-controlled study. Neurol Neuroimmunol Neuroinflamm 2017;4:e398. [PMID: 28955715 DOI: 10.1212/NXI.0000000000000398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
57 Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8:223-233. [PMID: 24011513 DOI: 10.1016/j.crohns.2013.08.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
58 Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, Renna H, Lu Y. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1441-1449. [PMID: 23567780 DOI: 10.1097/mib.0b013e318281341b] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
59 Rivera-Izquierdo M, Valero-Ubierna MDC, Nieto-Gómez P, Martínez-Bellón MD, Fernández-Martínez NF, Barranco-Quintana JL. Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. Expert Rev Vaccines 2020;19:727-44. [PMID: 32702246 DOI: 10.1080/14760584.2020.1800462] [Reference Citation Analysis]
60 Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. J Can Assoc Gastroenterol 2021;4:e72-91. [PMID: 34476339 DOI: 10.1093/jcag/gwab016] [Reference Citation Analysis]
61 Mill J, Lawrance IC. Preventing infective complications in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9691-9698 [PMID: 25110408 DOI: 10.3748/wjg.v20.i29.9691] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
62 Törüner M, Kalkan İH, Akyüz F, Tezel A, Çelik AF. Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic. Turk J Gastroenterol 2021;32:488-92. [PMID: 34405814 DOI: 10.5152/tjg.2021.280721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Baranowska-Nowak M, IwaŃczak B, Szczepanik M, Banasiuk M, DembiŃski Ł, Karolewska-Bochenek K, Dziekiewicz M, Radzikowski A, Banaszkiewicz A. Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease. Cent Eur J Immunol 2020;45:144-50. [PMID: 33456324 DOI: 10.5114/ceji.2020.97902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285. [PMID: 24839622 DOI: 10.1155/2014/941245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
65 Chaudrey K, Salvaggio M, Ahmed A, Mahmood S, Ali T. Updates in vaccination: Recommendations for adult inflammatory bowel disease patients. World J Gastroenterol 2015; 21(11): 3184-3196 [PMID: 25805924 DOI: 10.3748/wjg.v21.i11.3184] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
66 Scharrer S, Kutschera M, Weseslindtner L, Primas C, Vogelsang H. Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2021;33:443-7. [PMID: 33522752 DOI: 10.1097/MEG.0000000000002094] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-133. [PMID: 23295703 DOI: 10.1159/000342738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
68 Dave M, Purohit T, Razonable R, Loftus EV. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196-212. [PMID: 24051931 DOI: 10.1097/mib.0b013e3182a827d2] [Cited by in Crossref: 75] [Cited by in F6Publishing: 30] [Article Influence: 9.4] [Reference Citation Analysis]
69 Bousvaros A, Lu Y. Immunizations in the Child with Inflammatory Bowel Disease. In: Mamula P, Grossman AB, Baldassano RN, Kelsen JR, Markowitz JE, editors. Pediatric Inflammatory Bowel Disease. Cham: Springer International Publishing; 2017. pp. 663-8. [DOI: 10.1007/978-3-319-49215-5_54] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Banaszkiewicz A, Targońska B, Kowalska-Duplaga K, Karolewska-Bochenek K, Sieczkowska A, Gawrońska A, Grzybowska-Chlebowczyk U, Krzesiek E, Łazowska-Przeorek I, Kotowska M, Sienkiewicz E, Walkowiak J, Gregorek H, Radzikowski A, Albrecht P. Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:1607-14. [PMID: 25919976 DOI: 10.1097/MIB.0000000000000406] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
71 Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, Abraham B, Hudesman D, Malter L, McCabe R, Holubar S, Afzali A, Cheifetz AS, Gaidos JKJ, Moss AC. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab155. [PMID: 34279600 DOI: 10.1093/ibd/izab155] [Reference Citation Analysis]
72 Shrestha MP, Ruel J, Taleban S. Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol 2017;30:273-86. [PMID: 28469357 DOI: 10.20524/aog.2017.0130] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Mohme S, Schmalzing M, Müller CSL, Vogt T, Goebeler M, Stoevesandt J. Immunizations in immunocompromised patients: a guide for dermatologists. J Dtsch Dermatol Ges 2020;18:699-723. [PMID: 32713146 DOI: 10.1111/ddg.14156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Cossio-gil Y, Martínez-gómez X, Campins-martí M, Rodrigo-pendás JÁ, Borruel-sainz N, Rodríguez-frías F, Casellas-jordà F. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination: Hepatitis B vaccine in bowel disease. J Gastroenterol Hepatol 2015;30:92-8. [DOI: 10.1111/jgh.12712] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
75 Lenti MV, Mengoli C, Vernero M, Aronico N, Conti L, Borrelli de Andreis F, Cococcia S, Di Sabatino A. Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease. Front Immunol 2020;11:485. [PMID: 32269571 DOI: 10.3389/fimmu.2020.00485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
77 Wu X, Lin J, Buch H, Ding Q, Zhang F, Cui B, Ji G. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study. Front Public Health 2021;9:731578. [PMID: 34708016 DOI: 10.3389/fpubh.2021.731578] [Reference Citation Analysis]
78 Siegel CA, Melmed GY, McGovern DPB, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70:635-640. [PMID: 33472895 DOI: 10.1136/gutjnl-2020-324000] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 35.0] [Reference Citation Analysis]
79 Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. J Cutan Med Surg 2019;23:50-74. [PMID: 30463418 DOI: 10.1177/1203475418811335] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
80 Marín AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11273-11281 [PMID: 26527572 DOI: 10.3748/wjg.v21.i40.11273] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
81 Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, Ruan B. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. Vaccine. 2017;35:2633-2641. [PMID: 28404358 DOI: 10.1016/j.vaccine.2017.03.080] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
82 Cushing KC, Kanuri N, Ciorba MA. Pneumococcal Disease in Inflammatory Bowel Disease: Justification to Vaccinate at Diagnosis. Gastroenterology 2016;151:365-6. [PMID: 27375193 DOI: 10.1053/j.gastro.2016.06.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
83 Tung J, Kane S, Enders FT, Jeavons EN. Hepatitis B Vaccine in IBD. American Journal of Gastroenterology 2013;108:620-1. [DOI: 10.1038/ajg.2013.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
84 Wagner N, Assmus F, Arendt G, Baum E, Baumann U, Bogdan C, Burchard G, Föll D, Garbe E, Hecht J, Müller-ladner U, Niehues T, Überla K, Vygen-bonnet S, Weinke T, Wiese-posselt M, Wojcinski M, Zepp F. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsbl 2019;62:494-515. [DOI: 10.1007/s00103-019-02905-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 27] [Article Influence: 20.0] [Reference Citation Analysis]
85 Andrisani G, Armuzzi A, Marzo M, Felice C, Pugliese D, Papa A, Guidi L. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016; 7(3): 387-396 [PMID: 27602239 DOI: 10.4292/wjgpt.v7.i3.387] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
86 Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, Lee SH, Seo GS, Park SJ, Choi CH, Jung SA, Hong SN, Im JP, Kim ES; Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014;8:384-91. [PMID: 24144611 DOI: 10.1016/j.crohns.2013.09.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
87 Nguyen DL, Nguyen ET, Bechtold ML. Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis. Dig Dis Sci 2015;60:2446-53. [PMID: 25796579 DOI: 10.1007/s10620-015-3631-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
88 van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine 2018;36:5832-45. [PMID: 30122649 DOI: 10.1016/j.vaccine.2018.07.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
89 Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol 2018;16:99-105. [PMID: 28870657 DOI: 10.1016/j.cgh.2017.08.041] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
90 Casella G, Ingravalle F, Ingravalle A, Monti C, Bonetti F, De Salvatore F, Villanacci V, Limonta A. Vaccination in Inflammatory Bowel Disease: Utility and Future Perspective. GastrointestDisord 2020;2:175-92. [DOI: 10.3390/gidisord2020019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Love BL, Finney CJ, Gaidos JKJ. Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients. J Crohns Colitis 2021;15:1279-83. [PMID: 33491047 DOI: 10.1093/ecco-jcc/jjab017] [Reference Citation Analysis]
92 Kumar A, Quraishi MN, Segal JP, Raine T, Brookes MJ. COVID-19 vaccinations in patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol 2020;5:965-6. [PMID: 32971020 DOI: 10.1016/S2468-1253(20)30295-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
93 Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Goodhand JR, Hart AL, Lees CW, Ahmad T, Powell N, Chukwurah I, Haq S, Shah P, Wilken-smith S, Ramanathan A, Patel M, Romanczuk L, King R, Domingo J, Shamtally D, Mendoza V, Sanchez J, Stark H, Knight B, Bee L, Estember C, Barnes A, Watkins D, Stone S, Kirkwood J, Parkinson M, Gardner-thorpe H, Covil K, Derikx L, Gros Alcalde B, Lee I, Cipriano B, Ruocco G, Baden M, Cooke G, Pollock K. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00005-x] [Reference Citation Analysis]
94 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
95 Zullow S, Farraye FA. Updates on vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2019;13:229-39. [PMID: 30791761 DOI: 10.1080/17474124.2019.1565993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
96 Johnson SD, Olwenyi OA, Bhyravbhatla N, Thurman M, Pandey K, Klug EA, Johnston M, Dyavar SR, Acharya A, Podany AT, Fletcher CV, Mohan M, Singh K, Byrareddy SN. Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. World J Gastroenterol 2021; 27(29): 4763-4783 [PMID: 34447225 DOI: 10.3748/wjg.v27.i29.4763] [Reference Citation Analysis]
97 Kantsø B, Halkjær SI, Østergaard Thomsen O, Belard E, Gottschalck IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up. Infect Dis (Lond) 2019;51:651-8. [PMID: 31290715 DOI: 10.1080/23744235.2019.1638519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
98 Manolakis CS, Cash BD. Health Maintenance and Inflammatory Bowel Disease. Curr Gastroenterol Rep 2014;16. [DOI: 10.1007/s11894-014-0402-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
99 Weaver KN, Zhang X, Dai X, Watkins R, Adler J, Dubinsky MC, Kastl A, Bousvaros A, Strople JA, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda E, Farraye FA, Boccieri ME, Firestine A, Kappelman MD, Long MD. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Inflamm Bowel Dis 2021:izab302. [PMID: 34871388 DOI: 10.1093/ibd/izab302] [Reference Citation Analysis]
100 García-Serrano C, Mirada G, Marsal JR, Ortega M, Sol J, Solano R, Artigues EM, Estany P. Compliance with the guidelines on recommended immunization schedule in patients with inflammatory bowel disease: implications on public health policies. BMC Public Health 2020;20:713. [PMID: 32429900 DOI: 10.1186/s12889-020-08850-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
101 Garcia Garrido HM, Vollaard A, D’haens GR, Spuls PI, Bemelman FJ, Tanck MW, de Bree GJ, Meek B, Grobusch MP, Goorhuis A. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy. Vaccines 2022;10:795. [DOI: 10.3390/vaccines10050795] [Reference Citation Analysis]